CN102015717A - 趋化因子受体调节剂 - Google Patents

趋化因子受体调节剂 Download PDF

Info

Publication number
CN102015717A
CN102015717A CN2009801150516A CN200980115051A CN102015717A CN 102015717 A CN102015717 A CN 102015717A CN 2009801150516 A CN2009801150516 A CN 2009801150516A CN 200980115051 A CN200980115051 A CN 200980115051A CN 102015717 A CN102015717 A CN 102015717A
Authority
CN
China
Prior art keywords
formula
unsubstituted
alkyl
compounds
another embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801150516A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·P·克拉克
马克·A·洛克伍德
佛罗伦萨·F·瓦格纳
迈克尔·G·纳特楚斯
布兰登·C·多洛
特丽夏·L·约翰逊
耶希姆·阿尔塔斯·塔希洛维克
劳伦斯·威尔逊
约翰·M·怀斯曼
贾森·W·斯谷德拉瑞克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALTIRIS THERAPEUTICS
Original Assignee
ALTIRIS THERAPEUTICS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALTIRIS THERAPEUTICS filed Critical ALTIRIS THERAPEUTICS
Publication of CN102015717A publication Critical patent/CN102015717A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2009801150516A 2008-03-28 2009-03-30 趋化因子受体调节剂 Pending CN102015717A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4051608P 2008-03-28 2008-03-28
US61/040,516 2008-03-28
PCT/US2009/038805 WO2009121063A2 (en) 2008-03-28 2009-03-30 Chemokine receptor modulators

Publications (1)

Publication Number Publication Date
CN102015717A true CN102015717A (zh) 2011-04-13

Family

ID=41114825

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801150516A Pending CN102015717A (zh) 2008-03-28 2009-03-30 趋化因子受体调节剂

Country Status (14)

Country Link
US (2) US8338448B2 (https=)
EP (2) EP2262808B1 (https=)
JP (1) JP5690715B2 (https=)
KR (1) KR20110005819A (https=)
CN (1) CN102015717A (https=)
AU (1) AU2009228034A1 (https=)
BR (1) BRPI0909375A2 (https=)
CA (1) CA2718618A1 (https=)
DK (1) DK2262808T3 (https=)
IL (1) IL208185A0 (https=)
MX (1) MX2010010619A (https=)
NZ (1) NZ587929A (https=)
SG (1) SG189723A1 (https=)
WO (1) WO2009121063A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109553604A (zh) * 2017-09-25 2019-04-02 苏州云轩医药科技有限公司 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用
CN110669036A (zh) * 2018-07-02 2020-01-10 苏州云轩医药科技有限公司 一类具有cxcr4信号通路抑制活性的杂环化合物及其应用

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100518160B1 (ko) * 1996-11-05 2006-09-18 닛폰 프라파렛트 가부시키가이샤 합성수지팔레트
AU2009228034A1 (en) 2008-03-28 2009-10-01 Altiris Therapeutics Chemokine receptor modulators
EP3153510B1 (en) 2010-12-03 2020-05-06 Emory University Fused azines as chemokine cxcr4 receptor modulators and uses related thereto
CN105120863B (zh) * 2013-03-14 2021-06-04 奥斯特克有限公司 促进骨生长的烷基胺骆驼蓬碱衍生物
EP3143005B1 (en) 2014-05-16 2021-07-07 Emory University Chemokine cxcr4 and ccr5 receptor modulators and used related thereto
WO2016048861A2 (en) * 2014-09-22 2016-03-31 National Health Research Institutes Heterocyclic compounds and use thereof
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
PL3393468T3 (pl) 2015-12-22 2023-01-23 X4 Pharmaceuticals, Inc. Metody leczenia niedoboru odporności
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
EP3321264A1 (en) * 2016-11-14 2018-05-16 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Selective inhibitors of genotoxic stress-induced ikk/nf-kb pathways
EP3585387A4 (en) 2017-02-21 2020-08-12 Emory University CHEMIOKIN CXCR4 RECEIVER MODULATORS AND THEIR USES
US12384830B2 (en) 2017-06-02 2025-08-12 Regents Of The University Of Minnesota Compositions and methods for improving immunotherapy
KR102678977B1 (ko) * 2017-09-25 2024-06-28 씨젠테크 (쑤저우, 차이나) 컴퍼니 리미티드 Cxcr4 저해제로서 헤테로아릴 화합물, 그 조성물 및 이용 방법
JP7282786B2 (ja) * 2017-09-25 2023-05-29 シージーンテック （スーチョウ， チャイナ） カンパニー リミテッド Ｃｘｃｒ４阻害剤としてのヘテロアリール化合物、それを用いた組成物及び方法
US11649235B2 (en) 2018-03-19 2023-05-16 Emory University Pan-tropic entry inhibitors
CA3109104A1 (en) 2018-08-14 2020-02-20 Osteoqc Inc. Fluoro .beta.-carboline compounds
CA3108714A1 (en) 2018-08-14 2020-02-20 Osteoqc Inc. Pyrrolo - dipyridine compounds
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia
US20240293391A1 (en) * 2021-06-24 2024-09-05 Katholieke Universiteit Leuven Isoquinoline and pyridine based cxcr4 antagonists
WO2024220485A2 (en) * 2023-04-18 2024-10-24 The Regents Of The University Of California Dual inhibitors of dyrk1a and 5-ht2 for treating a brain disorder

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631265A (en) * 1994-03-11 1997-05-20 Eli Lilly And Company 8-substituted tetrahydro-beta-carbolines
CN1596255A (zh) * 2001-12-21 2005-03-16 阿诺麦德股份有限公司 具有强效的与趋化因子受体结合的杂环化合物
WO2005048916A3 (en) * 2003-11-20 2007-12-13 Biovitrum Ab Tetrahydrospiro-beta-carboline-1,3 '-pyrrolidine derivatives and their use in ghsr-related disorders

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US5993817A (en) * 1995-01-23 1999-11-30 Xenotech Method to ameliorate osteolysis and metastasis
US6358915B1 (en) 1995-03-07 2002-03-19 George Washington University Methods for inhibiting metastasis
AU6390696A (en) 1995-06-20 1997-01-22 Trustees Of Boston University Hypoxia-responsive adhesion molecules, specific antibodies, nd their uses
US6344545B1 (en) * 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US5922676A (en) 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
WO1999028474A2 (en) 1997-12-01 1999-06-10 The Government Of The United States Of America, Represented By The Secretary Of Health And Human Services Chemokine variants and methods of use
WO1999047158A2 (en) 1998-03-13 1999-09-23 The University Of British Columbia Therapeutic chemokine receptor antagonists
WO1999057149A2 (en) 1998-05-05 1999-11-11 Adherex Technologies, Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
EP1050583A4 (en) * 1998-11-24 2005-02-02 Hisamitsu Pharmaceutical Co INHIBITORS OF HIV INFECTIONS
US6750348B1 (en) * 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
BR0010655A (pt) 1999-03-24 2002-02-13 Anormed Inc Compostos heterocìclicos para ligação ao receptor de quimiocina
WO2001038352A2 (en) 1999-11-24 2001-05-31 Schering Corporation Methods of inhibiting metastasis
CA2369056A1 (en) 2000-02-03 2001-08-09 Thomas Jefferson University Vmip-ii peptide antagonists of cxcr4
DE60103052T2 (de) 2000-05-09 2005-03-03 The University Of British Columbia, Vancouver Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
US6835731B2 (en) * 2000-09-15 2004-12-28 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
WO2002094261A1 (fr) 2001-05-24 2002-11-28 Kureha Chemical Industry Company, Limited Medicaments antagonistes de cxcr4 comprenant un compose contenant de l'azote
US20040254221A1 (en) 2001-09-28 2004-12-16 Toru Yamazaki Novel Nitrogenous Compound and use thereof
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
WO2004020462A1 (ja) 2002-08-27 2004-03-11 Fujii, Nobutaka Ｃｘｃｒ４拮抗薬およびその用途
DE10240064A1 (de) 2002-08-30 2004-03-11 Universitätsklinikum Freiburg CXCR4-Rezeptor-Antagonisten
US20040132642A1 (en) * 2002-11-12 2004-07-08 Government Of The U.S.A., Represented By The Secretary, Dept. Of Health & Human Services Methods of inhibiting metastasis or growth of a tumor cell
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
JP2006524242A (ja) 2003-03-27 2006-10-26 エモリー ユニバーシティー Ｃｘｃｒ４アンタゴニストおよびそれらの使用方法
EP1613613B1 (en) 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
AU2004232361A1 (en) 2003-04-22 2004-11-04 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
WO2006074428A2 (en) 2005-01-07 2006-07-13 Emory University Cxcr4 antagonists for the treatment of medical disorders
AU2006203826A1 (en) * 2005-01-07 2006-07-13 Emory University CXCR4 antagonists for the treatment of HIV infection
EP2041067A4 (en) 2006-07-11 2009-11-25 Univ Emory CXER4 ANTAGONISTS WITH DIAZINE AND TRIAZINE STRUCTURES FOR THE TREATMENT OF MEDICAL PROBLEMS
WO2008008852A2 (en) 2006-07-11 2008-01-17 Emory University Cxcr4 antagonists including heteroatoms for the treatment of medical disorders
US20080227799A1 (en) * 2006-07-11 2008-09-18 Liotta Dennis C CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders
US20080261978A1 (en) * 2007-03-08 2008-10-23 Clark Michael P Chemokine receptor modulators
US20080293711A1 (en) * 2007-03-08 2008-11-27 Clark Michael P Chemokine receptor modulators
AU2009228034A1 (en) 2008-03-28 2009-10-01 Altiris Therapeutics Chemokine receptor modulators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631265A (en) * 1994-03-11 1997-05-20 Eli Lilly And Company 8-substituted tetrahydro-beta-carbolines
CN1596255A (zh) * 2001-12-21 2005-03-16 阿诺麦德股份有限公司 具有强效的与趋化因子受体结合的杂环化合物
WO2005048916A3 (en) * 2003-11-20 2007-12-13 Biovitrum Ab Tetrahydrospiro-beta-carboline-1,3 '-pyrrolidine derivatives and their use in ghsr-related disorders

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109553604A (zh) * 2017-09-25 2019-04-02 苏州云轩医药科技有限公司 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用
CN109553604B (zh) * 2017-09-25 2021-08-27 盛世泰科生物医药技术(苏州)有限公司 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用
CN110669036A (zh) * 2018-07-02 2020-01-10 苏州云轩医药科技有限公司 一类具有cxcr4信号通路抑制活性的杂环化合物及其应用
CN110669036B (zh) * 2018-07-02 2022-02-11 盛世泰科生物医药技术(苏州)有限公司 一类具有cxcr4信号通路抑制活性的杂环化合物及其应用

Also Published As

Publication number Publication date
DK2262808T3 (da) 2013-11-04
SG189723A1 (en) 2013-05-31
KR20110005819A (ko) 2011-01-19
JP5690715B2 (ja) 2015-03-25
US20100029634A1 (en) 2010-02-04
WO2009121063A3 (en) 2010-01-07
BRPI0909375A2 (pt) 2015-08-04
EP2664618A3 (en) 2014-05-07
EP2262808A2 (en) 2010-12-22
US9314468B2 (en) 2016-04-19
EP2664618A2 (en) 2013-11-20
WO2009121063A2 (en) 2009-10-01
EP2262808A4 (en) 2011-11-16
JP2011516427A (ja) 2011-05-26
NZ587929A (en) 2012-10-26
EP2262808B1 (en) 2013-08-14
CA2718618A1 (en) 2009-10-01
US8338448B2 (en) 2012-12-25
IL208185A0 (en) 2010-12-30
MX2010010619A (es) 2010-12-17
US20130172330A1 (en) 2013-07-04
AU2009228034A1 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
JP5690715B2 (ja) ケモカイン受容体調節因子
TWI752580B (zh) Kras突變蛋白抑制劑
TWI836159B (zh) 可作為helios蛋白質抑制劑之化合物
JP7321194B2 (ja) セレブロン（ｃｒｂｎ）に対するリガンド
KR102849047B1 (ko) 피롤로피리미딘 itk 억제제
KR102835667B1 (ko) Parp14 억제제로서의 퀴나졸리논
US8729271B2 (en) Glycine transporter inhibiting substances
CN113423701A (zh) 取代的异吲哚啉酮
KR20190012167A (ko) 이소퀴놀린-3-일 카르복스아마이드 및 이의 제제와 용도
CZ20013421A3 (cs) Heterocyklické sloučeniny váľící chemokinové receptory
EP2884981A2 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
US8742132B2 (en) Indolylmaleimide derivatives processes for their production and pharmaceutical compositions
MX2014012574A (es) Imidazolil-pirimidinas sustituidas con amino-indolilo y su uso como medicamentos.
CN100439365C (zh) 用作蛋白激酶抑制剂的化合物和组合物
JP2010527999A (ja) ＰＫＣ−θ阻害剤としてのプリノン類および１Ｈ−イミダゾピリジノン類
KR101710127B1 (ko) 야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민
JP2006241089A (ja) ピロロピリミジン誘導体またはその塩
AU2006268908A1 (en) Indolylmaleimide derivatives
CA2861442C (en) Piperazinyl pyrimidine derivatives, preparation method and use thereof
HK1156619A (en) Chemokine receptor modulators
KR20210135274A (ko) Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
WO2025215188A1 (en) Therapeutic compounds and their use as inhibitors of pkmyt1
AU2013203978A1 (en) Chemokine receptor modulators

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1156619

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110413

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1156619

Country of ref document: HK